Kadcyla and Splenomegaly - a phase IV clinical study of FDA data

Summary:

Splenomegaly is reported as a side effect among people who take Kadcyla (ado-trastuzumab emtansine), especially for people who are female, 50-59 old, have been taking the drug for 1 - 2 years also take Herceptin, and have Breast cancer.

The phase IV clinical study analyzes which people have Splenomegaly when taking Kadcyla. It is created by eHealthMe based on reports of 5,798 people who have side effects when taking Kadcyla from the FDA, and is updated regularly.

What is Kadcyla?

Kadcyla has active ingredients of ado-trastuzumab emtansine. eHealthMe is studying from 5,813 Kadcyla users. Check the latest studies of Kadcyla.

What is Splenomegaly?

Splenomegaly (enlargement of spleen) is found to be associated with 1,121 drugs and 1,477 conditions by eHealthMe. Check the latest studies of Splenomegaly.

On Jul, 13, 2026

5,798 people reported to have side effects when taking Kadcyla.
Among them, 28 people (0.48%) have Splenomegaly.

Among these 28 people:

How long have people been on Kadcyla when they have Splenomegaly? *

What is the gender of people who have Splenomegaly when taking Kadcyla? *

female: 100 %
male: 0.0 %

What is the age of people who have Splenomegaly when taking Kadcyla? *

What are other drugs people take besides Kadcyla? *

What are other side effects people have besides Splenomegaly? *

Thrombocytopenia (decrease of platelets in blood): 8 people, 28.57%
Portal Hypertension (increase in the blood pressure within a system of veins called the portal venous system): 6 people, 21.43%
Hepatomegaly (abnormal enlargement of the liver): 4 people, 14.29%
Cough: 3 people, 10.71%
Hepatic Cyst: 3 people, 10.71%
Hepatic Cirrhosis (chronic liver disease characterized by replacement of liver tissue by fibrosis, scar tissue): 3 people, 10.71%
Disease Progression: 3 people, 10.71%
Pain: 3 people, 10.71%
Pneumonia: 3 people, 10.71%
Idiopathic Pulmonary Fibrosis (chronic lung disease): 3 people, 10.71%

What are the existing conditions these people have? *

Breast Cancer: 11 people, 39.29%
Breast Cancer Metastatic: 9 people, 32.14%
Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection): 2 people, 7.14%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 1 person, 3.57%
Neuropathy Peripheral (surface nerve damage): 1 person, 3.57%
Metastases To Liver (cancer spreads to liver): 1 person, 3.57%
Metastases To Bone (cancer spreads to bone): 1 person, 3.57%
High Blood Pressure: 1 person, 3.57%

* Approximation only. Some reports may have incomplete information.

Do you take Kadcyla and have Splenomegaly?

- Check whether Splenomegaly is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Kadcyla:

Kadcyla (5,813 reports)

Splenomegaly treatments and more:

Splenomegaly (17,257 reports)

Browse all side effects of Kadcyla:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Splenomegaly:

Splenomegaly (1,121 drugs)

Browse all the conditions that are associated with Splenomegaly:

Splenomegaly (1,477 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ado-trastuzumab emtansine (the active ingredients of Kadcyla) and Kadcyla (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.